Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 7Phase 3 6Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 81Leukemia 33Precursor Cell Lymphoblastic Leukemia-Lymphoma 25Myelodysplastic Syndromes 22Recurrence 13Congenital Abnormalities 12Lymphoma, Non-Hodgkin 9Leukemia, Biphenotypic, Acute 9Burkitt Lymphoma 9Lymphoma, Mantle-Cell 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Monocytic, Acute 7Hodgkin Disease 7Lymphoma 6Leukemia, Myelomonocytic, Acute 6Leukemia, Megakaryoblastic, Acute 6Leukemia, Erythroblastic, Acute 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Myeloproliferative Disorders 4Lymphoma, Follicular 4Lymphoma, B-Cell 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Leukemia, Prolymphocytic 3Leukemia, Myeloid 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hematologic Neoplasms 3Blast Crisis 3

Interventions

tipifarnib 1Idarubicin 1Cytarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia, Eosinophilic, Acute × Cytarabine × Clear all
NCT00096122 2014-05-26

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
95 enrolled 5 charts
Classical hematologyOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡